Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 13;13:840173. doi: 10.3389/fimmu.2022.840173

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 de Almeida, Berzoti-Coelho, Toro, Cacemiro, Bassan, Barretto, Garibaldi, Palma, de Figueiredo-Pontes, Sorgi, Faciolli, Gardinassi and de Castro

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Dynamic of the abundance of metabolite features associated with disease progression and response to TKI therapy. (A) One-way hierarchical clustering based on the intensity of highly significant metabolite features selected by ANOVA. (B) Metabolic pathways enriched by significant metabolite features. (C) Up- and downregulated abundant metabolites in patients in advanced (AP)/resistant (RT) vs. chronic phase (CP), AP/RT vs. remission post-TKI (RM), and CP vs. RM. (D) Metabolic pathways enriched by significant metabolite features. The circle size represents the number of differentially abundant metabolites, and the circle color means the degree of significance (p-value magnitude) after comparison between the control and CML patient groups.